Stockscreener 앱 받기
7.36
0.68%
0.05
시간 외 거래:
7.26
-0.10
-1.36%
전일 마감가:
$7.31
열려 있는:
$7.21
하루 거래량:
2.27M
Relative Volume:
13.12
시가총액:
$6.75M
수익:
-
순이익/손실:
$-14.93M
주가수익비율:
-0.0277
EPS:
-266.137
순현금흐름:
$-15.87M
1주 성능:
+14.29%
1개월 성능:
-14.52%
6개월 성능:
-12.90%
1년 성능:
-92.47%
1일 변동 폭
$6.50
$8.20
1주일 범위
$6.50
$8.20
52주 변동 폭
$6.0829
$468.44
트랜스코드 테라 Stock (RNAZ) Company Profile
명칭
Transcode Therapeutics Inc
전화
857-301-6857
주소
6 LIBERTY SQUARE, BOSTON
RNAZ을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RNAZ
Transcode Therapeutics Inc
|
7.36 | 6.70M | 0 | -14.93M | -15.87M | -266.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
트랜스코드 테라 주식(RNAZ)의 최신 뉴스
TransCode Therapeutics Publishes Preclinical Data Supporting TTX-MC138 for Glioblastoma Treatment - citybuzz -
TransCode’s glioblastoma therapy shows promise in preclinical study By Investing.com - Investing.com South Africa
Transcode Therapeutics Ttx-Mc138 phase 2a clinical trial expected in first half of 2026 - marketscreener.com
Transcode Therapeutics Ttx-Mc138 Phase 2A Clinical Trial Expected In First Half Of 2026 - TradingView — Track All Markets
TransCode Therapeutics reports promising preclinical glioblastoma results - TipRanks
TransCode Therapeutics stock soars after promising glioblastoma study By Investing.com - Investing.com Canada
TransCode Therapeutics Publishes Preclinical Data on TTX-MC138 for Glioblastoma - TradingView — Track All Markets
Experimental RNA therapy extends survival in brain cancer animal tests - Stock Titan
Precision Trading with Transcode Therapeutics Inc. (RNAZ) Risk Zones - Stock Traders Daily
TransCode Therapeutics appoints Jack E. Stover to board of directors By Investing.com - Investing.com Nigeria
TransCode Therapeutics Appoints Industry Veteran Jack E. Stover to Board of Directors - citybuzz -
TransCode Therapeutics Strengthens Board with Veteran Financial Expert - TipRanks
Transcode Therapeutics Appoints Jack Stover to Board of Directors - TradingView — Track All Markets
TransCode Therapeutics appoints Jack E. Stover to board of directors - Investing.com India
TransCode Therapeutics expands leadership with appointment of Jack E. Stover to board of directors - marketscreener.com
Transcode Therapeutics Expands Leadership With Appointment Of Jack E. Stover To Board Of Directors - TradingView — Track All Markets
Life sciences leader behind a $900M pharma sale joins cancer firm - Stock Titan
Why TransCode Therapeutics Inc. stock is favored by top institutionsQuarterly Market Summary & Real-Time Buy Zone Alerts - Улправда
TransCode Therapeutics Earnings Notes - Trefis
Is TransCode Therapeutics Inc. stock in correction or buying zoneJuly 2025 Sector Moves & Free Risk Controlled Daily Trade Plans - DonanımHaber
How TransCode Therapeutics Inc. stock benefits from tech adoptionMarket Volume Summary & Daily Profit Maximizing Trade Tips - Улправда
TransCode Therapeutics (NASDAQ:RNAZ) Shares Down 4.6% – Here’s What Happened - Defense World
MSN Money - MSN
TransCode Therapeutics Inc Stock Analysis and ForecastMACD Histogram Signals & Superior Trading Ideas - earlytimes.in
TransCode and Quantum Leap to test cancer therapy in phase 2a trial - Investing.com Australia
TransCode Therapeutics and Quantum Leap Collaborate on Colorectal Cancer Trial Targeting Metastatic Disease - citybuzz
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
TransCode and Quantum Leap to test cancer therapy in phase 2a trial By Investing.com - Investing.com South Africa
TransCode Therapeutics and Quantum Leap Healthcare Collaborative launch a phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's phase 1 trial - marketscreener.com
TransCode Therapeutics Announces Phase 2a Trial Collaboration - TradingView — Track All Markets
TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's Phase 1 trial - PR Newswire
Buyout Rumor: Why hedge funds are buying NETSTREIT Corp. stockInsider Selling & Expert Curated Trade Ideas - moha.gov.vn
Critical Comparison: TransCode Therapeutics (NASDAQ:RNAZ) & ReNeuron Group (OTCMKTS:RNUGF) - Defense World
Will TransCode Therapeutics Inc. stock see PE expansion2025 Growth vs Value & Low Risk Profit Maximizing Plans - Newser
Is TransCode Therapeutics Inc. stock supported by strong cash flows2025 Top Gainers & AI Enhanced Execution Alerts - Newser
Alzamend Neuro (ALZN) Stock Analysis Report | Financials & Insights - Benzinga
TransCode Therapeutics To Acquire Polynoma, Receive $25M Investment To Advance Key Asset - MSN
Is TransCode Therapeutics Inc. stock a contrarian buyRecession Risk & Technical Pattern Recognition Alerts - newser.com
TransCode Therapeutics, Inc. (RNAZ) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Real time breakdown of TransCode Therapeutics Inc. stock performanceEarnings Growth Report & Free Expert Verified Stock Movement Alerts - newser.com
What technical models suggest about TransCode Therapeutics Inc.’s comeback2025 Dividend Review & Accurate Buy Signal Alerts - newser.com
Can TransCode Therapeutics Inc. stock deliver strong Q4 earningsJuly 2025 Pullbacks & Daily Market Momentum Tracking - newser.com
Is TransCode Therapeutics Inc. stock resilient to inflationMarket Risk Summary & Long-Term Capital Growth Ideas - newser.com
TransCode Therapeutics Inc. recovery potential after sell offQuarterly Earnings Summary & Long-Term Capital Growth Ideas - newser.com
Will TransCode Therapeutics Inc. stock outperform value stocks2025 Market Sentiment & Breakout Confirmation Trade Signals - newser.com
Avidity Biosciences Inc. (RNA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Why retail investors favor TransCode Therapeutics Inc. stockWeekly Market Outlook & Weekly High Return Stock Opportunities - newser.com
트랜스코드 테라 (RNAZ) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.52%
0.07%
자본화:
|
볼륨(24시간):